Genmab A/S is an international biotechnology company with a pipeline of novel antibody-based products and product candidates designed to address medical needs and improve treatment outcomes for patients with cancer and other serious diseases.
Genmab generates revenue from product sales in territories where it leads commercialization, milestone payments under collaboration agreements, and royalties from partnered products. The company records sales for epcotamab in the US…
Genmab A/S is an international biotechnology company with a pipeline of novel antibody-based products and product candidates designed to address medical needs and improve treatment outcomes for patients with cancer and other serious diseases.
Genmab generates revenue from product sales in territories where it leads commercialization, milestone payments under collaboration agreements, and royalties from partnered products. The company records sales for epcotamab in the US and Japan and for tisotumab vedotin in Europe, Japan and rest of world markets excluding the US and China. Genmab receives tiered royalties on global sales of epcotamab outside the US and Japan and on tisotumab vedotin sales in certain regions. Additionally, the company earns royalties on net sales of six marketed medicines developed by partners using its technology platforms: daratumumab, rybrevant, teclistamab, and talquetamab (all commercialized by J&J), kesimpta (Novartis), tepotumumab (Amgen), and bizengri (Partner Therapeutics). Milestone payments from collaborations with companies such as AbbVie, Pfizer, BioNTech, and others also contribute to revenue.
Genmab holds a significant position in the biotechnology industry through its proprietary antibody technology platforms and pipeline of clinical-stage product candidates. The company faces intense competition in the cancer drug sector from large pharmaceutical companies, specialty biotechs, and academic institutions. Key competitors vary by product: for epcotamab, these include Regeneron's odronextamab, Roche's mosunetuzumab and glofitamab; for tisotumab vedotin, competitors include checkpoint inhibitors from Merck, Bristol Myers Squibb, and others; for partnered products like daratumumab, competition includes Sanofi's isatuximab and GSK's belantamab mafodotin. Genmab's competitive advantages stem from its DuoBody, HexaBody, DuoHexaBody, HexElect, and ADC technology platforms, which enable the creation of novel antibody-based therapeutics. The company's strategy of retaining significant rights in its product candidates and selectively collaborating with partners allows it to maximize value from its innovations while expanding its pipeline.
Genmab serves patients with cancer and other serious diseases through its therapeutic products. The company's direct business customers include pharmaceutical and biotechnology companies that collaborate on development and commercialization. Specific customer names for partnership revenues are J&J for daratumumab, rybrevant, teclistamab, and talquetamab; Novartis for kesimpta; Amgen for tepotumumab; and Partner Therapeutics for bizengri. For its own commercialized products, Genmab works with AbbVie on epcotamab joint commercialization and with Pfizer on tisotumab vedotin joint promotion in the United States, while leading commercialization efforts independently in other regions.